Date: 2015-09-15
Type of information: Nomination
Compound:
Company: Celyad previously known as Cardio3 Bioscience (Belgium)
Therapeutic area: Cardiovascular diseases - Regenerative medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 15, 2015, Celyad announced the appointment of Dr. Frederic Lehmann to the newly created position of Vice President Immuno-Oncology, effective September 14, 2015. In this role, Dr. Lehmann will be responsible for Celyad’s overall oncology franchise. His objective will be to develop and implement a growth strategy aimed at positioning the Company as a leader in engineered cell therapies for immuno-oncology applications, building upon Celyad’s lead oncology product candidate, Natural Killer Receptor NKG2D CAR T-cell. Dr. Vincent Brichard will continue to provide strategic advice as a representative of ViaNova SPRL to explore the full potential of the immuno-oncology portfolio. Dr. Lehmann has extensive experience in oncology drug development spanning early to late phase, including clinical trial design, translational research, regulatory interactions, and clinical risk management. He is a physician by training and started his academic career at the Ludwig Institute for Cancer Research in Brussels, followed by a position at the Institute Jules Bordet. He then moved to the European Organization for Research and Treatment of Cancer (EORTC) as Medical Advisor. Dr. Lehmann began his corporate career at GSK, where he led the early worldwide clinical development program for the Company’s cancer vaccines and went on to lead the research and development incubator for cancer immunotherapeutics. Dr. Lehmann qualified as an MD and has a Master’s degree in Hematology in Oncology.
Financial terms:
Latest news:
